SMARCA4: Current status and future perspectives in non-small-cell lung cancer

被引:38
|
作者
Tian, Yumeng [1 ]
Xu, Lu [1 ]
Li, Xin [1 ]
Li, Heming [1 ,2 ]
Zhao, Mingfang [1 ,2 ]
机构
[1] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang 110001, Peoples R China
[2] China Med Univ, Hosp 1, Dept Med Oncol, 155 Nanjingbei Rd, Shenyang 110001, Liaoning, Peoples R China
关键词
NSCLC; SMARCA4; gene; SMARCA2; SWI/SNF complex; Immunotherapy; CHROMATIN-REMODELING FACTOR; TUMOR-SUPPRESSOR; SYNTHETIC LETHAL; SWI/SNF COMPLEX; CLINICOPATHOLOGICAL CHARACTERISTICS; DOWN-REGULATION; BAF COMPLEXES; DNA-DAMAGE; BRG1; MUTATIONS;
D O I
10.1016/j.canlet.2022.216022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that participates in the regulation of chromatin structure and gene expression by supplying energy. As a tumor suppressor that has aberrant expression in similar to 10% of non-small-cell lung cancers (NSCLCs), SMARCA4 possesses many biological functions, including regulating gene expression, differentiation and transcription. Furthermore, NSCLC patients with SMARCA4 alterations have a weak response to conventional chemotherapy and poor prognosis. Therefore, the mechanisms of SMARCA4 in NSCLC development urgently need to be explored to identify novel biomarkers and precise therapeutic strategies for this subtype. This review systematically describes the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigenetics and potential therapeutic approaches for NSCLCs with SMARCA4 alterations. Additionally, this paper explores the relationship and regulatory mechanisms shared by SMARCA4 and its mutually exclusive catalytic subunit SMARCA2. We aim to provide innovative treatment strategies and improve clinical outcomes for NSCLC patients with SMARCA4 alterations.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
    Feld, Emily
    Horn, Leora
    ONCOTARGETS AND THERAPY, 2017, 10 : 3697 - 3708
  • [32] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
    Jiabao Hou
    Hongle Li
    Shuxiang Ma
    Zhen He
    Sen Yang
    Lidan Hao
    Hanqiong Zhou
    Zhe Zhang
    Jing Han
    Li Wang
    Qiming Wang
    Biomarker Research, 10
  • [33] SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
    Xue, Yibo
    Meehan, Brian
    Fu, Zheng
    Wang, Xue Qing D.
    Fiset, Pierre Olivier
    Rieker, Ralf
    Levins, Cameron
    Kong, Tim
    Zhu, Xianbing
    Morin, Genevieve
    Skerritt, Lashanda
    Herpel, Esther
    Venneti, Sriram
    Martinez, Daniel
    Judkins, Alexander R.
    Jung, Sungmi
    Camilleri-Broet, Sophie
    Gonzalez, Anne V.
    Guiot, Marie-Christine
    Lockwood, William W.
    Spicer, Jonathan D.
    Agaimy, Abbas
    Pastor, William A.
    Dostie, Josee
    Rak, Janusz
    Foulkes, William D.
    Huang, Sidong
    NATURE COMMUNICATIONS, 2019, 10
  • [34] SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
    Yibo Xue
    Brian Meehan
    Zheng Fu
    Xue Qing D. Wang
    Pierre Olivier Fiset
    Ralf Rieker
    Cameron Levins
    Tim Kong
    Xianbing Zhu
    Geneviève Morin
    Lashanda Skerritt
    Esther Herpel
    Sriram Venneti
    Daniel Martinez
    Alexander R. Judkins
    Sungmi Jung
    Sophie Camilleri-Broet
    Anne V. Gonzalez
    Marie-Christine Guiot
    William W. Lockwood
    Jonathan D. Spicer
    Abbas Agaimy
    William A. Pastor
    Josée Dostie
    Janusz Rak
    William D. Foulkes
    Sidong Huang
    Nature Communications, 10
  • [35] Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
    Armon, Subasri
    Hofman, Paul
    Ilie, Marius
    CELLS, 2021, 10 (08)
  • [36] SMARCA4 deficiency in small cell lung cancer: A case report and narrative review of the literature
    Matthaiou, Andreas M.
    Tomos, Ioannis
    Bizymi, Nikoleta
    Vamvakaris, Ioannis
    Anagnostopoulos, Nektarios
    Papadopoulou, Aikaterini
    Angelou, Kalliopi
    Stratakos, Grigoris
    Liapikou, Adamantia
    BIOMOLECULES AND BIOMEDICINE, 2025,
  • [37] EVALUATION OF CURRENT CLINICAL STATUS AND FUTURE-DIRECTIONS IN NON-SMALL-CELL LUNG-CANCER - DISCUSSION
    BUNN, PA
    HARA
    BISHOP, JF
    BONOMI, P
    YONEDA
    NIITANI, H
    NEGORO
    ONCOLOGY, 1992, 49 : 78 - 79
  • [38] SMARCA4 deficient non-small cell lung cancer (NSCLC): A comprehensive genomic profiling (CGP) study
    Graziano, S. L.
    Lin, D.
    Elvin, J. A.
    Vergilio, J-A.
    Killian, J. K.
    Ngo, N.
    Ramkissoon, S.
    Severson, E.
    Hemmerich, A.
    Duncan, D.
    Edgerly, C.
    Ali, S. M.
    Schrock, A. B.
    Chung, J.
    Sokol, E. S.
    Reddy, P.
    McGregor, K.
    Miller, V. A.
    Alexander, B. M.
    Ross, J. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 652 - +
  • [39] Chromatin remodeling factor SMARCA4 as a predictive biomarker of cisplatin therapy in non-small cell lung cancer
    Chakraborty, Arup R.
    Bell, Erica
    Mo Xiaokui
    Liu, Ziyan
    Shilo, Konstantin
    Kirste, Simon
    Stegmaier, Petra
    McNulty, Maureen
    Karachaliou, Niki
    Rosell, Rafael
    Bepler, Gerold
    Carbone, David P.
    Chakravarti, Arnab
    CANCER RESEARCH, 2016, 76
  • [40] Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives
    Haddad, Fady G.
    Kourie, Hampig R.
    Kattan, Joseph
    FUTURE ONCOLOGY, 2017, 13 (03) : 201 - 204